Key facts
- Abarceo Pharma’s last known valuation is $7.0M (Jan 2023).
- It has raised $3.5M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Almi Invest, Alsteron, Cardeon (Private Equity), EIT Health, LU Innovation (Lund) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Abarceo Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Abarceo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abarceo Pharma
Developer of therapeutic drug candidates intended to address mitochondrial dysfunction in metabolic disease. The company develops small molecule compounds that target mitochondrial proteins implicated in beta cell impairment, with research programs focused on restoring cellular energy regulation, enabling healthcare systems, pharmaceutical partners, and patients affected by type two diabetes and comorbid diseases to access disease-modifying treatment approaches that aim to support durable metabolic control and improved clinical outcomes.
- Sector
- Healthcare
- HQ
- Malmo, Sweden
- Founded
- 2017
- Employees
- 10
- Website
- abarceo.com/
- Ownership
- Privately Held (backing)
Abarceo Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abarceo Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abarceo Pharma in its N-PORT filings yet. We sweep new filings monthly.